Lin Aimee Bence - Oncology, Eli Lilly and Company

基本信息

浏览量：73

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 60 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Round-Robin Comparison of RET Rearrangement Detection in Ctdna: A Novel Method for Limited Clinical Samples

Cloud P Paweletz, Alison Urvalek, Minh Ha,Kavita Garg,Aimee Bence Lin,Anna M Szpurka, Anthony Sireci,Geoffrey R Oxnard,Pasi A Janne

Clinical cancer research an official journal of the American Association for Cancer Researchno. 12 (2025): 2406-2412

引用0浏览0WOS引用

MOONRAY-01, a Phase 1 Study of LY3962673, a Potent, Orally Bioavailable, and Selective KRAS G12D Inhibitor in KRAS G12D -Mutant Solid Tumors

Nehal J. Lakhani,Davide Melisi,Vivek Subbiah,Natraj Reddy Ammakkanavar,Eileen M. O'Reilly,Philippe Alexandre Cassier,Zev A. Wainberg, Austin G. Duffy,Amita Patnaik,Yutaka Fujiwara,Paul Eliezer Oberstein,Rocio Garcia-Carbonero,Jennifer Wright,Aimee K. Lin, Jian Li, Michael D. Axelson,Ignacio Garrido-Laguna

Journal of Clinical Oncologyno. 4_suppl (2025)

引用0浏览0引用

Patient-reported Outcomes of First-Line Selpercatinib Versus Chemotherapy with or Without Pembrolizumab in RET Fusion-Positive Advanced Non-Small Cell Lung Cancer: Interim Analysis of LIBRETTO-431

Koichi Goto,Silvia Novello,Pilar Garrido,Christophe Dooms,Jorge Alatorre-Alexander,Niels Reinmuth,Adrienne Gilligan,Nalin Payakachat,Aimee Bence-Lin,Kim Cocks,Gill Worthy,Caicun Zhou

ONCOLOGY RESEARCH AND TREATMENT (2024): 246-246

引用0浏览0引用

Efficacy and Safety of 1L Selpercatinib in RET Fusion-Positive NSCLC: LIBRETTO-431 East Asian Subgroup Analysis

Ying Cheng,Herbert H. Loong,Caicun Zhou,Kazumi Nishino,Dae Ho Lee,Se-Hoon Lee,James Chih-Hsin Yang, Dan Liu, Deborah Rajakumar,Hongmei Han,Tarun Puri,Aimee Bence Lin,Koichi Goto

JOURNAL OF CLINICAL ONCOLOGYno. 23_SUPPL (2024): 214-214

引用1浏览0引用

Supplemental Data from the Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma

Caitlin D. Lowery,Alle B. VanWye,Michele Dowless,Wayne Blosser,Beverly L. Falcon,Julie Stewart,Jennifer Stephens,Richard P. Beckmann,Aimee Bence Lin,Louis F. Stancato

openalex（2023）

引用0浏览0引用

Supplementary Table 2 from A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

openalex（2023）

引用0浏览0引用

Supplementary Figures 1 and 2 and Supplementary Tables 1 Through 3 from A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

openalex（2023）

引用0浏览0引用

Supplementary Tables 1-4. Supplementary Figure 1 from Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

David S. Hong, Kathleen Moore,Manish Patel,Stefan C. Grant,Howard A. Burris,William N. William,Suzanne Jones, Funda Meric-Bernstam,Jeffrey Infante,Lisa Golden,Wei Zhang, Ricardo Martinez,Sameera Wijayawardana,Richard Beckmann,Aimee Bence Lin,Cathy Eng,Johanna Bendell

openalex（2023）

引用0浏览0引用

490MO Patient-reported Outcomes of First-Line Selpercatinib Versus Chemotherapy with or Without Pembrolizumab in RET Fusion-Positive Advanced Non-Small Cell Lung Cancer: Interim Analysis of LIBRETTO-431

K. Goto,S. Novello,P. Garrido Lopez,C. Dooms,J.A. Alatorre Alexander,N. Reinmuth,A. Gilligan,N. Payakachat,A. Lin,K. Cocks,G. Worthy,C. Zhou

Annals of Oncology（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn